Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Verrica Pharmaceuticals Inc.

< Previous 1 2 Next >
Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers TVTX VRCA
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Provides Business and Operational Update
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Announces Pricing of $42.0 Million Public Offering
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Announces Proposed Public Offering
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Tickers VRCA
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.